Atenolol And Chlorthalidone

Associated with severe bradycardia, asystole, and heart failure when combined with beta-blockers due to potent negative inotropic and chronotropic effects.

Diuretic component reduces lithium renal clearance, creating high risk of lithium toxicity. Generally should not be given together.

Antiarrhythmic with negative chronotropic properties that may be additive to beta-blocker effects, increasing bradycardia risk.

Additive effects may occur when given with atenolol and chlorthalidone, potentially causing excessive cardiovascular depression.

Beta-blockers may exacerbate rebound hypertension following clonidine withdrawal; beta-blocker should be withdrawn several days before gradual clonidine cessation.

Both drugs slow atrioventricular conduction and decrease heart rate; concomitant use increases bradycardia risk.

Patients with history of anaphylaxis may have more severe reactions and may be unresponsive to usual doses of epinephrine during beta-blocker therapy.

Catecholamine depletor may cause severe hypotension and marked bradycardia with vertigo, syncope, or postural hypotension.

Prostaglandin synthase inhibitor may decrease hypotensive effects of beta-blockers.

Thiazides may decrease arterial responsiveness to norepinephrine, though this does not preclude therapeutic effectiveness.

Thiazides may increase responsiveness to tubocurarine.

Drug Interactions Atenolol and chlorthalidone tablets may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone tablets plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone tablets (See WARNINGS ).